Pfizer reports better-than-expected Q2 results despite low sales of Prevnar

While sales of the popular vaccine Prevnar fell short, Pfizer still reported better-than-expected revenue thanks to strong sales from new treatments.

The New York City-based drugmaker's second quarter revenue increased 11 percent year over year to $13.2 billion.

Prevnar, a vaccine for pneumococcal diseases, saw a decline in sales posting $1.26 billion, compared to the $1.58 billion analysts predicted, according to Bloomberg.

Sales of Ibrance — Pfizer's new breast cancer drug — more than tripled to hit $514 million, surpassing analysts' estimate of $498 million.

Pfizer's new arthritis pill Xeljanz posted 217 million in sales, beating its $199 million projection.

Pfizer reported total earnings of $2.02 billion, or 33 cents a share, a decrease from the $2.63 billion, or 42 cents per share, the company recorded for the second quarter of 2015.

More articles on the drug market:

Express Scripps adds new drugs to its exclusion list
Teva must divest 79 generics to acquire Allergan's generic pharma for $40.5 billion
MIT researchers create programmable device to produce biologics on the spot

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.